Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,712,397
  • Shares Outstanding, K 320,741
  • Annual Sales, $ 1,435 M
  • Annual Income, $ 231,060 K
  • 60-Month Beta 0.74
  • Price/Sales 3.96
  • Price/Cash Flow 22.89
  • Price/Book 2.47
Trade EXEL with:

Options Overview Details

View History
  • Implied Volatility 42.94% ( -2.11%)
  • Historical Volatility 51.60%
  • IV Percentile 32%
  • IV Rank 20.87%
  • IV High 77.66% on 07/28/21
  • IV Low 33.78% on 06/24/21
  • Put/Call Vol Ratio 0.64
  • Today's Volume 228
  • Volume Avg (30-Day) 447
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 28,390
  • Open Int (30-Day) 30,720

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.21
  • Number of Estimates 6
  • High Estimate 0.25
  • Low Estimate 0.16
  • Prior Year 0.30
  • Growth Rate Est. (year over year) -30.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.37 +11.12%
on 05/19/22
23.13 -21.36%
on 04/29/22
-4.06 (-18.25%)
since 04/26/22
3-Month
16.37 +11.12%
on 05/19/22
23.40 -22.26%
on 04/05/22
-1.99 (-9.86%)
since 02/25/22
52-Week
15.50 +17.35%
on 12/06/21
23.52 -22.66%
on 06/25/21
-4.21 (-18.79%)
since 05/26/21

Most Recent Stories

More News
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022

Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from multiple cohorts of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX ® ) as a monotherapy and in combination with atezolizumab...

EXEL : 18.19 (+2.13%)
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib (CABOMETYX ® ) in combination with pembrolizumab in patients with recurrent or metastatic...

EXEL : 18.19 (+2.13%)
Buy the Dip: 2 Growth Stocks to Add to Your Portfolio

Escalating fears over inflationary pressures, the Federal Reserve’s tighter monetary policy, and slow economic growth have caused a massive sell-off in growth stocks over the past few weeks. But the...

EXEL : 18.19 (+2.13%)
Can This Cancer Stock Maintain Its Momentum?

This biotech stock has been on fire since the beginning of the year.

EXEL : 18.19 (+2.13%)
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

XBI : 68.47 (+1.09%)
BCRX : 9.05 (+2.84%)
ARNA : 99.99 (+0.06%)
EXEL : 18.19 (+2.13%)
IBB : 115.80 (+0.90%)
FBT : 133.78 (+1.13%)
Buying These 3 Stocks Could Be the Smartest Investing Move You Ever Make

With thrilling long-term prospects, these three are excellent buys.

ISRG : 223.30 (+0.32%)
EXEL : 18.19 (+2.13%)
ETSY : 78.25 (+9.30%)
Exelixis (EXEL) Q1 2022 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2022.

EXEL : 18.19 (+2.13%)
Exelixis (EXEL) Q1 Earnings Beat, Revenues Miss Estimates

Exelixis (EXEL) beats on earnings but misses on revenues in the first quarter. While the top line increases on a year-over-year basis, the bottom line improves from the year-ago breakeven figure.

BMY : 77.59 (+0.45%)
PFE : 53.99 (+0.52%)
MRK : 92.31 (-1.54%)
EXEL : 18.19 (+2.13%)
Exelixis (EXEL) Tops Q1 Earnings Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of 50% and 6.02%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

EXEL : 18.19 (+2.13%)
ALBO : 20.05 (-0.59%)
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical...

EXEL : 18.19 (+2.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 19.51
2nd Resistance Point 19.05
1st Resistance Point 18.62
Last Price 18.19
1st Support Level 17.73
2nd Support Level 17.27
3rd Support Level 16.84

See More

52-Week High 23.52
Fibonacci 61.8% 20.46
Fibonacci 50% 19.51
Fibonacci 38.2% 18.56
Last Price 18.19
52-Week Low 15.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar